Meditrina
Meditrina is a San Jose-based medical technology company that develops the Aveta System, an all-in-one single-use hysteroscopy platform combining HD visualization, fluid management, and tissue resection, sold to OB/GYNs, ambulatory surgery centers, and hospitals in the US, UK, and EU.
- Company typePrivate
- Founded2016
- HeadquartersSan Jose, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Meditrina does
Meditrina, Inc. is a privately held medical technology company founded in 2016 and headquartered in San Jose, California, that develops and commercializes the Aveta System, an integrated single-use hysteroscopy platform for treating intrauterine pathology. The platform combines HD video visualization, fluid management, and tissue resection into a single compact controller unit that fits office, procedure-room, and operating-room settings. Core hardware includes patented single-use hysteroscopes (Aveta Pearl at 5.7mm with 4mm working channel, Aveta Coral at 4.6mm with 3mm working channel, and Aveta Opal for office use), a portfolio of disposable resecting devices (Aveta Smol, Flex+, Max+, Auto, and Glo bipolar RF), and accessories for fluid and waste management. Differentiators cited include the smallest insertion diameter with the largest expandable working channel, SteadiView automatic image orientation lock, 5X faster tissue resection than MyoSure and TruClear per bench studies, and 10-minute faster OR turnover per clinical evaluation.
The company sells through a field-based direct sales organization of Territory Managers and Senior Territory Managers targeting OB/GYNs, ambulatory surgery centers, and hospital systems in the United States, and through a distribution partnership with M.E.D. Surgical (a division of Uniphar Medtech) for Ireland and the United Kingdom. Revenue is generated primarily through sale of single-use sterile hysteroscopes and resecting devices — a consumable, per-procedure model that aligns with hospital and ASC volume economics. Pricing is quote-based with multi-year contracts; specific tier pricing is not publicly disclosed. Meditrina has secured FDA 510(k) clearance (original 2019, Gen 2 Bipolar RF 2024), CE Mark, and UKCA Mark, and holds 17 granted US patents covering its core technology.
The company has raised over $100 million cumulatively since 2019 across equity and debt tranches, including a $77 million Series C led by Deerfield Management with ShangBay Capital in May 2024 at a $500 million pre-money valuation. Deerfield's Steven Hochberg and ShangBay Capital's William Dai sit on the board. Meditrina is led by Founder, President and CEO Csaba Truckai, with Matt Fratantoro as VP Sales and Marketing, Abbey Taylor as Director of Clinical Marketing, and Ray Gerena as SVP of Global Sales. As of 2024-2025, the company has stated it is approaching cash flow positive and is using Series C proceeds to accelerate new product introductions and expand its sales force.
Meditrina firmographics
Firmographics- Name
- Meditrina
- Legal name
- Meditrina, Inc.
- Website
- https://avetasystem.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Meditrina is a San Jose-based medical technology company that develops the Aveta System, an all-in-one single-use hysteroscopy platform combining HD visualization, fluid management, and tissue resection, sold to OB/GYNs, ambulatory surgery centers, and hospitals in the US, UK, and EU.
- Ownership category
- akta.pro rank
Meditrina industry classification
Industry- Product category
- Gynecologic Surgical Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools) (HLAHADAN)
- akta.pro secondary industries
- Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS) (HLAHADAA), Minimally Invasive Gynecologic Surgery (Laparoscopy/Hysteroscopy) (HLAKAJAF), Single-Use Medical Disposables & Procedure Kits (Drapes, Tubing, Catheters, Syringes, Custom Packs) (HLAHANAG)
Keywords
Where Meditrina is headquartered
LocationHeadquarters
- HQ city
- San Jose
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Meditrina business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Personnel, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- Single-use Medical Devices: Sale of single-use sterile hysteroscopes (Aveta Coral, Aveta Pearl, Aveta Opal) and resecting devices (Aveta Smol, Aveta Flex+, Aveta Max+, Aveta Auto) that are disposed of after each procedure. These consumable devices are sold to hospitals, ASCs, and physician offices performing hysteroscopy procedures.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom enterprise pricing based on facility type and volume |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels6 records
Meditrina product offering
Product offeringCore offering
Meditrina develops, manufactures, and sells the Aveta System, an all-in-one hysteroscopy platform that combines HD video visualization, integrated fluid management, and tissue resection in a single compact unit. The product line includes single-use hysteroscopes (Aveta Pearl, Aveta Coral, Aveta Opal) and disposable resecting devices (Aveta Smol, Flex+, Max+, Auto, Glo) used by OB/GYNs to treat intrauterine pathologies such as fibroids, polyps, and retained products of conception in office, clinic, and operating room settings.
Product overview
Meditrina offers the Aveta System, a unified all-in-one tissue removal platform for intrauterine pathology treatment. The portfolio centers on the Aveta System core platform combining HD video, fluid management, and tissue resection, supported by multiple single-use hysteroscope options (Aveta Pearl for myomectomy, Aveta Coral for polypectomy, Aveta Opal for office-based procedures) and pathology-optimized resecting devices (Aveta Smol, Flex+, Max+ for different tissue densities, plus Aveta Auto and Aveta Glo Bipolar RF). Accessories include the System Controller, Head Up Display, Fluid Management Accessory, and Waste Management Accessory. The system is FDA 510(k) cleared, CE-marked, and UKCA-marked for use in office, clinic, and hospital operating room settings.
Differentiator
Problem solved
Functional benefit
Brands
- Aveta System: The Aveta System is the company's flagship product - an all-in-one tissue removal solution for intrauterine pathology, combining HD video, fluid management, and tissue resection in a single seamless system for hysteroscopy procedures.
- Aveta Coral
- Aveta Pearl
- Aveta Opal
- Aveta Smol
- Aveta Flex+
- Aveta Max+
- Aveta Glo
Products and services
- Aveta System All-in-one tissue removal solution for intrauterine pathology combining HD video, fluid management, and tissue resection in a single compact system designed for office, procedure, and operating room settings. Targeted at OB/GYNs performing hysteroscopic procedures.
- Aveta Pearl Hysteroscope Single-use 5.7mm insertion diameter hysteroscope with 4mm working channel, optimized for myomectomy procedures. Features integrated camera, LED light source, and SteadiView imaging technology.
- Aveta Coral Hysteroscope Single-use 4.6mm insertion diameter hysteroscope with 3mm working channel, optimized for polypectomy procedures. Features integrated camera, LED light source, and SteadiView imaging technology with automatic upright image orientation.
- Aveta Opal HD Hysteroscope Single-use 4.6mm insertion diameter hysteroscope with 3.0mm working channel, designed for office-based polyp removal without requiring fluid management. Part of the Aveta Office Suite.
- Aveta Smol Resecting Device 2.9mm disposable resecting device optimized for soft tissue and polyps with 30g/min tissue removal rate.
- Aveta Flex+ Resecting Device 2.9mm flexible disposable resecting device for polyps and soft/dense fibroids with 59g/min polyp and 19.3g/min fibroid tissue removal rates.
- Aveta Max+ Resecting Device 3.9mm disposable resecting device designed for hard, dense fibroids with 42g/min tissue removal rate.
- Aveta Auto Resecting Device 2.9mm motorized disposable resecting device with internal suction pump and integrated tissue specimen container, designed for office-based procedures. Eliminates manual hand squeezing for tissue resection.
- Aveta Glo Bipolar RF Device Bipolar radiofrequency resecting device introduced with the Gen 2 system, enabling more controlled tissue removal with hemostasis and deeper myometrial wall penetration for fibroid treatment.
Quantifiable outcome
- 5X faster tissue resection compared to MyoSure and TruClear systems
- +4 more outcomes
Companies that use Meditrina
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles3 records
Meditrina technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Meditrina partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and key hire.
- M.E.D. Surgical (Uniphar Medtech)coreStrategic partnership for distribution of the Aveta System throughout Ireland and the United Kingdom. M.E.D. Surgical, a division of Uniphar Medtech, brings its extensive distribution network to distribute Meditrina's women's health technology. The partnership combines M.E.D. Surgical's distribution expertise with Meditrina's innovative medical device technology.
- Ray Gerenakey hireAppointed as Senior Vice President of Global Sales to strengthen Meditrina's commitment to driving growth and expanding its global footprint. Brings extensive experience and leadership in strategic sales initiatives.
Scale indicators5 records
Recent moves6 records
Expansion highlights7 records
Meditrina competitors and assessment
Company assessmentDirect peers
- Hologic: Owner of the MyoSure hysteroscopic tissue removal system, the most direct incumbent competitor to Meditrina's Aveta System. Competes head-to-head in operative hysteroscopy for fibroids and polyps in the same OB/GYN call point.
- Stryker: Through its TruClear system, Stryker is the second named incumbent in operative hysteroscopic tissue resection. The two systems are explicitly benchmarked against Aveta in Meditrina's 5X resection speed claim.
- Richard Wolf: Specialist endoscopy manufacturer with a dedicated gynecologic resection and hysteroscopy product line. Direct competitor in minimally invasive gynecologic surgery equipment and disposables.
- CooperSurgical: Focused women's health medical device company selling hysteroscopy fluid management, scopes, and office-based gynecologic products. Competes directly with Aveta, particularly in office and ASC settings.
Broad incumbents
- Karl Storz: Global leader in rigid and flexible endoscopy, including a large hysteroscopy franchise with reusable scopes and resectoscopes. Comparable as a broad endoscopic incumbent with overlapping gynecologic surgery products.
- Olympus: Diversified endoscopy giant with hysteroscopy products integrated into its broader gynecologic and urologic visualization portfolio. Competes in the same OR/ambulatory surgery channels as Meditrina.
- Boston Scientific: Large women's health and endoscopy franchise including tissue resection tools used in hysteroscopic procedures. Competes for the same hospital capital budgets and OB/GYN surgeon relationships.
Emerging players
- Minerva Surgical: Emerging women's health device company focused on endometrial ablation and intrauterine pathology treatment — adjacent to hysteroscopy, founded by overlapping entrepreneur/investor ecosystem and competing for the same OB/GYN budget.
Regional players
- Lina Medical: European-focused hysteroscopy and gynecologic endoscopy specialist. Comparable in product category and call point, primarily serving EMEA markets where Meditrina is just beginning to expand.
Others
- Hologic (MyoSure NovaSure) ancillary — Conmed: Gynecologic surgery device manufacturer (including hysteroscopy and resectoscope products) that is an indirect adjacent competitor and ecosystem participant in the OR and ASC channels Meditrina targets.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Meditrina social profiles
Digital presenceMeditrina compliance and trust
Trust signalCompliance3 records
Meditrina financial estimates
Financial estimateRevenue estimate
Valuation estimate
Meditrina leadership team
Management profileNumber of profiles
Profiles6 records
Meditrina funding detail
Funding detailFunding overview
Funding rounds3 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Meditrina M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Meditrina
What does Meditrina do?
Meditrina develops, manufactures, and sells the Aveta System, an all-in-one hysteroscopy platform that combines HD video visualization, integrated fluid management, and tissue resection in a single compact unit. The product line includes single-use hysteroscopes (Aveta Pearl, Aveta Coral, Aveta Opal) and disposable resecting devices (Aveta Smol, Flex+, Max+, Auto, Glo) used by OB/GYNs to treat intrauterine pathologies such as fibroids, polyps, and retained products of conception in office, clinic, and operating room settings.
Is Meditrina a public or private company?
Meditrina is a private company. It is classified as venture growth investor backed and is currently operating.
When was Meditrina founded?
Meditrina was founded in 2016. It employs 51 to 100 people.
Where is Meditrina based?
Meditrina is headquartered in San Jose, United States, in the North America region.
How does Meditrina make money?
One revenue line is on record: single-use Medical Devices.
Who are Meditrina's main competitors?
Direct peers on record are Hologic, Stryker, Richard Wolf and CooperSurgical. Broad incumbents are Karl Storz, Olympus and Boston Scientific. Minerva Surgical is listed as an emerging player. Lina Medical is listed as a regional player. Hologic (MyoSure NovaSure) ancillary — Conmed is listed as an others.
Does Meditrina have an API?
No public API is recorded for Meditrina.
What industry is Meditrina in?
Meditrina's product category is Gynecologic Surgical Devices. Its primary akta.pro industry code is HLAHADAN, Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools), with a secondary code of HLAHADAA, Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS). Its NAICS code is 339112 and its SIC code is 3841.